This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|February 22, 2022
Quotient Sciences Completes Integration of Drug Substance into Translational Pharmaceutics Platform
Author(s)BioPharm International Editors
Quotient Sciences announces that it has integrated drug substance into its flagship Translational Pharmaceutics platform.
Advertisement
Quotient Sciences announced on Feb. 17, 2022 that it has integrated drug substance into its flagship Translational Pharmaceutics platform. This newly integrated service combines drug substance, drug product, and clinical testing activities all under one unified organization and project manager.
The approach of combining manufacturing and clinical dosing at a single organization allows innovators to adjust formulations and dosing in real time. Translational Pharmaceutics was developed in consultation with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and FDA and utilizes a rapid “make-test” cycle, where drug products are manufactured, released, and dosed in a clinical study in days rather than months.
“Our Translational Pharmaceutics platform is now in its 15th year and has accelerated development timelines for more than 500 drug programs,” commented Mark Egerton, CEO of Quotient Sciences, in a press release. “We remain the only outsourcing partner able to offer innovators the ability to manufacture, release and dose under one organization. This approach is proven to shave 12 months off timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be further accelerated by 2–4 months.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5